<!DOCTYPE html>

<html lang="en" data-theme="light">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Calcium Balance & Bone Drugs - Essentials of Medical Pharmacology</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link
        href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap"
        rel="stylesheet">

    <link rel="stylesheet" href="../styles/main.css">

    <script>
        MathJax = {
            tex: {
                inlineMath: [['$', '$'], ['\\(', '\\)']],
                displayMath: [['$$', '$$'], ['\\[', '\\]']],
                processEscapes: true,
                processEnvironments: true
            },
            svg: { fontCache: 'global' },
            options: {
                skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
            }
        };
    </script>

    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>

</head>

<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>

    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <div class="reading-progress-container">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <!-- Floating TOC -->

    <nav class="floating-toc" id="floating-toc">
        <div class="floating-toc-header">
            <span>üìë</span> Table of Contents
        </div>
        <ul class="floating-toc-list">
            <li><a href="#regulation">Calcium Regulation</a></li>
            <li><a href="#pth">Parathormone (PTH)</a></li>
            <li><a href="#calcitonin">Calcitonin</a></li>
            <li><a href="#vitamind">Vitamin D</a></li>
            <li><a href="#bisphosphonates">Bisphosphonates</a></li>
            <li><a href="#other-agents">Other Bone Drugs</a></li>
            <li><a href="#osteoporosis">Osteoporosis Management</a></li>
        </ul>
    </nav>

    <div class="page-wrapper">
        <div class="container">
            <article class="document-article">
                <header class="document-header">
                    <div class="header-badge">
                        <span>ü¶¥</span>
                        <span>Topic 25</span>
                    </div>
                    <h1 class="document-title">Hormones and Drugs Affecting Calcium Balance</h1>
                    <div class="title-meta">
                        <div class="meta-item">
                            <span>üìö</span>
                            <span>Hormones and Related Drugs</span>
                        </div>
                        <div class="meta-item">
                            <span>‚è±Ô∏è</span>
                            <span>50 min read</span>
                        </div>
                    </div>
                </header>
                <main id="main-content" class="content-wrapper">
                    <!-- Section 1: Regulation -->
                    <section class="content-section" id="regulation">
                        <div class="section-header">
                            <div class="section-number">01</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚öñÔ∏è</span>
                                Calcium Regulation
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Plasma calcium level ($9-11$ mg/dl) is precisely regulated by three principal hormones:
                                <strong>Parathormone (PTH)</strong>, <strong>Calcitonin</strong>, and
                                <strong>Calcitriol</strong> (Active Vitamin D). They control intestinal absorption, bone
                                exchange, and renal excretion.</p>

                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Hormone</th>
                                            <th>Source</th>
                                            <th>Effect on Plasma Ca$^{2+}$</th>
                                            <th>Major Action</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>PTH</strong></td>
                                            <td>Parathyroid Glands</td>
                                            <td>Increases ($\uparrow$)</td>
                                            <td>Increases bone resorption, renal reabsorption, and Vit D activation.
                                            </td>
                                        </tr>
                                        <tr>
                                            <td><strong>Calcitonin</strong></td>
                                            <td>Thyroid Parafollicular Cells</td>
                                            <td>Decreases ($\downarrow$)</td>
                                            <td>Inhibits bone resorption (inhibits osteoclasts).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Calcitriol</strong></td>
                                            <td>Kidney (Activation)</td>
                                            <td>Increases ($\uparrow$)</td>
                                            <td>Increases intestinal absorption.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </section>

                    <!-- Section 2: PTH -->
                    <section class="content-section" id="pth">
                        <div class="section-header">
                            <div class="section-number">02</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü¶ã</span>
                                Parathormone (PTH) & Teriparatide
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>PTH secretion is regulated by plasma $Ca^{2+}$ concentration via calcium-sensing
                                receptors (CaSR). Hypocalcaemia stimulates PTH release.</p>
                            <h3>Actions</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><strong>Bone:</strong> Promotes resorption (mobilizes Ca).
                                    Continuous high levels activate osteoclasts (via RANKL induction in osteoblasts).
                                    However, <strong>intermittent low doses stimulate bone formation</strong>.</li>
                                <li class="list-item"><strong>Kidney:</strong> Increases $Ca^{2+}$ reabsorption (distal
                                    tubule) and phosphate excretion. Activates $1\alpha$-hydroxylase to generate active
                                    Vit D.</li>
                                <li class="list-item"><strong>Intestine:</strong> Indirectly increases Ca absorption via
                                    Calcitriol.</li>
                            </ul>

                            <h3>Teriparatide</h3>
                            <p>Recombinant human PTH (1-34 amino terminal). It is an <strong>anabolic agent</strong> for
                                bone.</p>
                            <div class="callout callout--success">
                                <div class="callout-header">
                                    <span class="callout-icon">‚úÖ</span>
                                    <h4 class="callout-title">Therapeutic Use</h4>
                                </div>
                                <div class="callout-content">
                                    <p>Used in <strong>severe osteoporosis</strong> (20 $\mu$g s.c. daily). Unlike
                                        bisphosphonates (which only stop resorption), teriparatide <strong>stimulates
                                            new bone formation</strong>, increasing bone mineral density and reducing
                                        fracture risk.</p>
                                </div>
                            </div>
                            <p><strong>Limitation:</strong> Use restricted to 2 years due to risk of osteosarcoma (seen
                                in rats).</p>

                            <h3>Cinacalcet</h3>
                            <p>A <strong>calcimimetic</strong> agent. It activates CaSR on parathyroid cells,
                                suppressing PTH secretion. Used in secondary hyperparathyroidism (CKD) and parathyroid
                                carcinoma.</p>
                        </div>
                    </section>

                    <!-- Section 3: Calcitonin -->
                    <section class="content-section" id="calcitonin">
                        <div class="section-header">
                            <div class="section-number">03</div>
                            <h2 class="section-title">
                                <span class="title-icon">üõë</span>
                                Calcitonin
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Hypocalcaemic hormone. Used clinically as <strong>Salmon Calcitonin</strong> (more
                                potent/longer acting than human).</p>
                            <h3>Actions</h3>
                            <p>Directly inhibits osteoclasts (via cAMP), reducing bone resorption. Also increases renal
                                Ca excretion.</p>
                            <h3>Uses</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><strong>Hypercalcaemia:</strong> Rapid action (4-6 hrs), but weak
                                    and transient (refractoriness develops). Adjuvant to fluids/bisphosphonates.</li>
                                <li class="list-item"><strong>Paget's Disease:</strong> Reduces bone pain and turnover.
                                    Second line to bisphosphonates.</li>
                                <li class="list-item"><strong>Postmenopausal Osteoporosis:</strong> Nasal spray. Less
                                    effective than other drugs; risk of malignancy has restricted use.</li>
                            </ul>
                        </div>
                    </section>

                    <!-- Section 4: Vitamin D -->
                    <section class="content-section" id="vitamind">
                        <div class="section-header">
                            <div class="section-number">04</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚òÄÔ∏è</span>
                                Vitamin D
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Synthesized in skin (D3, Cholecalciferol) or ingested (D2, Ergocalciferol). It is a
                                prohormone.</p>

                            <h3>Activation Pathway</h3>
                            <p>Skin/Diet $\rightarrow$ Liver (25-hydroxylation) $\rightarrow$ <strong>25-OH D3
                                    (Calcifediol)</strong> (Major circulating form) $\rightarrow$ Kidney
                                ($1\alpha$-hydroxylation via PTH) $\rightarrow$ <strong>1,25-(OH)2 D3
                                    (Calcitriol)</strong> (Active hormone).</p>

                            <h3>Actions</h3>
                            <p>Mediated via nuclear Vitamin D Receptors (VDR).</p>
                            <ul>
                                <li><strong>Intestine:</strong> Induces synthesis of calcium binding protein (Calbindin)
                                    $\rightarrow$ Promotes Ca and Phosphate absorption.</li>
                                <li><strong>Bone:</strong> Promotes mineralization (by maintaining plasma Ca/PO4).
                                    Essential for normal bone growth.</li>
                                <li><strong>Kidney:</strong> Enhances tubular reabsorption.</li>
                            </ul>

                            <h3>Preparations & Uses</h3>
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Preparation</th>
                                            <th>Indication</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Cholecalciferol (D3) / Ergocalciferol (D2)</strong></td>
                                            <td>Nutritional deficiency (Rickets, Osteomalacia). Prophylaxis.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Calcitriol</strong> (Active form)</td>
                                            <td><strong>Renal Osteodystrophy</strong> (Kidney cannot activate D3),
                                                Hypoparathyroidism.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Alfacalcidol</strong> ($1\alpha$-OH D3)</td>
                                            <td>Prodrug activated in liver (bypasses renal activation). Useful in renal
                                                bone disease.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </section>

                    <!-- Section 5: Bisphosphonates -->
                    <section class="content-section" id="bisphosphonates">
                        <div class="section-header">
                            <div class="section-number">05</div>
                            <h2 class="section-title">
                                <span class="title-icon">üß±</span>
                                Bisphosphonates
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Analogues of pyrophosphate (P-C-P bond). Most effective <strong>antiresorptive</strong>
                                drugs.</p>

                            <h3>Mechanism</h3>
                            <p>They concentrate in bones. When osteoclasts resorb bone, BPNs are released locally and
                                internalized. They inhibit the <strong>mevalonate pathway</strong> (FPP synthase)
                                $\rightarrow$ prevent protein prenylation $\rightarrow$ osteoclast apoptosis and loss of
                                function.</p>

                            <h3>Generations & Drugs</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><strong>1st Gen:</strong> Etidronate (Least potent, causes
                                    osteomalacia).</li>
                                <li class="list-item"><strong>2nd Gen (Amino-BPNs):</strong>
                                    <strong>Alendronate</strong>, Pamidronate. Potent.</li>
                                <li class="list-item"><strong>3rd Gen:</strong> <strong>Zoledronate</strong>,
                                    Risedronate, Ibandronate. Most potent.</li>
                            </ul>

                            <h3>Pharmacokinetics & Administration</h3>
                            <p>Oral bioavailability is very low (<1%). Food interferes with absorption.</p>
                                    <div class="callout callout--warning">
                                        <div class="callout-header">
                                            <span class="callout-icon">‚ö†Ô∏è</span>
                                            <h4 class="callout-title">Instructions for Oral Alendronate</h4>
                                        </div>
                                        <div class="callout-content">
                                            <p>Must be taken on an <strong>empty stomach</strong> in the morning with a
                                                full glass of water. Patient must remain <strong>upright</strong> for 30
                                                minutes. <strong>Why?</strong> To prevent prolonged contact with
                                                esophageal mucosa which causes severe <strong>esophagitis</strong> and
                                                ulceration.</p>
                                        </div>
                                    </div>

                                    <h3>Therapeutic Uses</h3>
                                    <ol>
                                        <li><strong>Osteoporosis:</strong> Postmenopausal, senile, and steroid-induced.
                                            Alendronate (70 mg/week), Risedronate, or Zoledronate (yearly i.v.) reduce
                                            fracture risk markedly.</li>
                                        <li><strong>Paget's Disease:</strong> Drug of choice (High dose).</li>
                                        <li><strong>Hypercalcaemia of Malignancy:</strong> <strong>Zoledronate</strong>
                                            (4 mg i.v.) or Pamidronate are highly effective (drug of choice).</li>
                                        <li><strong>Bone Metastasis:</strong> Reduce pain and fractures (Zoledronate,
                                            Pamidronate).</li>
                                    </ol>

                                    <h3>Adverse Effects</h3>
                                    <p>Esophagitis (oral), flu-like symptoms (i.v.), renal toxicity (Zoledronate),
                                        <strong>Osteonecrosis of the Jaw (ONJ)</strong> (rare, mainly with high dose
                                        i.v. in cancer patients), atypical femoral fractures (long term use).</p>
                        </div>
                    </section>

                    <!-- Section 6: Other Agents -->
                    <section class="content-section" id="other-agents">
                        <div class="section-header">
                            <div class="section-number">06</div>
                            <h2 class="section-title">
                                <span class="title-icon">üÜï</span>
                                Other Bone Drugs
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Denosumab</h3>
                            <p>Fully human monoclonal antibody against <strong>RANKL</strong>. It mimics the action of
                                Osteoprotegerin (OPG).</p>
                            <ul>
                                <li><strong>Mechanism:</strong> Binds RANKL $\rightarrow$ prevents activation of RANK on
                                    osteoclasts $\rightarrow$ inhibits osteoclast formation and activity.</li>
                                <li><strong>Use:</strong> Osteoporosis (s.c. every 6 months), bone metastasis.</li>
                                <li><strong>Advantages:</strong> Can be used in renal failure (unlike bisphosphonates).
                                </li>
                            </ul>

                            <h3>Strontium Ranelate</h3>
                            <p>Has dual action: inhibits bone resorption <strong>and</strong> stimulates bone formation.
                                Used as reserve drug (CV risk).</p>
                        </div>
                    </section>

                    <!-- Section 7: Osteoporosis Management -->
                    <section class="content-section" id="osteoporosis">
                        <div class="section-header">
                            <div class="section-number">07</div>
                            <h2 class="section-title">
                                <span class="title-icon">üìã</span>
                                Summary: Osteoporosis Management
                            </h2>
                        </div>

                        <div class="content-card">
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Class</th>
                                            <th>Drug Options</th>
                                            <th>Role</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Antiresorptive</strong></td>
                                            <td>Bisphosphonates (1st line)<br>Denosumab<br>Raloxifene (SERM)<br>HRT
                                                (Restricted use)</td>
                                            <td>Prevent further bone loss. Reduce fracture risk.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Anabolic</strong></td>
                                            <td>Teriparatide</td>
                                            <td>Builds new bone. For severe cases.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Supplements</strong></td>
                                            <td>Calcium + Vitamin D</td>
                                            <td>Essential adjuvant to all therapies.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </section>

                </main>

                <nav class="document-nav">
                    <div class="nav-container">
                        <a href="topic-24-uterine.html" class="nav-button nav-button--large nav-button--previous">
                            <div class="nav-label">Previous</div>
                            <div class="nav-title">Oxytocin & Uterine Drugs</div>
                        </a>

                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span>25</span>
                                <span class="progress-separator">/</span>
                                <span>27</span>
                            </div>
                            <div class="progress-bar-container">
                                <div class="progress-bar-fill" style="width: 92%;"></div>
                            </div>
                            <div class="progress-label">Topic Progress</div>
                        </div>

                        <a href="topic-26-muscle-relaxants.html" class="nav-button nav-button--large nav-button--next">
                            <div class="nav-label">Next</div>
                            <div class="nav-title">Skeletal Muscle Relaxants</div>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <script src="../js/theme.js"></script>

    <script src="../js/navigation.js"></script>

    <script src="../js/interactions.js"></script>

</body>

</html>